EGFR-specific tyrosine kinase inhibitors, including erlotinib, cetuximab, and gefitinib, reversibly inhibit EGFR by blocking its intracellular ATP-binding domain, thereby effectively treating metastatic lung cancer with EGFR mutations.298–300 Furthermore, ALK inhibitors such as crizotinib, ceritinib, and alectinib have demonstrated efficacy in treating brain metastasis in non-small cell lung cancer (NSCLC).301 Dasatinib, a Src kinase inhibitor that impedes cancer cell growth, is another promising antagonist.302. This evidence concerns the gene ALK and non-small cell lung carcinoma.